Swiss Tech Hardware Stock News

In recent days, Novartis reported Phase III data showing that Vanrafia slowed kidney function decline in IgA nephropathy and Cosentyx improved sustained remission and reduced steroid use in polymyalgia rheumatica, with results published and presented at major medical congresses. Together, these late-stage readouts highlight Novartis’s push to expand existing franchises into specialty kidney and rheumatology indications where treatment options are limited. Next, we’ll examine how Cosentyx’s...

Recent performance snapshot for PolyPeptide Group PolyPeptide Group (SWX:PPGN) has drawn attention after a mixed stretch for the stock, with the price down 3.4% on the day and about 9.2% over the past month, but up 53.3% over the past 3 months. At a last close of CHF 36.40 and a market value of roughly CHF 1.2b, the company operates in a specialist niche, supplying synthetic peptides as active ingredients and intermediates for a range of therapeutic products worldwide. See our latest analysis...

Kuehne + Nagel International (SWX:KNIN) is back in focus after an external research firm upgraded the stock to its highest rating, citing improved earnings prospects and a stronger underlying business outlook. See our latest analysis for Kuehne + Nagel International. The fresh upgrade comes after a period of improving momentum, with a 7-day share price return of 6.38% and a 90-day share price return of 10.96%, even though the 5-year total shareholder return is down 25.69%. If this shift in...

Recent share performance context ABB (SWX:ABBN) has been drawing attention after a period of strong multi year total returns and steady reported revenue and net income growth. This has prompted investors to reassess the stock’s recent move in relation to its fundamentals. See our latest analysis for ABB. The recent pullback, with a 1 day share price return of 1.84% and 7 day share price return of 0.62%, comes after a strong run, including a 90 day share price return of 25.11% and a 1 year...

Roche Holding (SWX:ROP) has received FDA Priority Review for giredestrant as an adjuvant therapy in ER-positive, HER2-negative early-stage breast cancer. The filing is supported by phase III lidERA data, which showed a significant improvement in disease-free survival compared with current standard-of-care endocrine therapy. The Priority Review focuses on use of giredestrant after surgery, where adjuvant options have seen limited change for more than two decades. Roche is a large global...

Why Partners Group’s redemption cap matters for shareholders Partners Group Holding (SWX:PGHN) has limited withdrawals from its $8.6b evergreen private equity fund to 5% of net asset value per quarter after redemption requests reached an estimated 9.8% in the second quarter. The stock has come under pressure, with shares down about 18% over the past month and roughly 31% year to date, as investors reassess liquidity risks and the business impact of tighter fund gates. See our latest analysis...

Tecan’s India move and what it means for the stock Tecan Group (SWX:TECN) has launched direct operations in India, setting up a local sales and service team in Gurugram and formalizing Tecan India as part of its broader regional expansion. This step follows the company’s move into South Korea in 2024 and gives Tecan closer access to pharmaceutical, biotechnology, academic and diagnostic customers in one of the fastest growing life sciences markets. See our latest analysis for Tecan Group. The...

As European markets navigate the complexities of geopolitical developments and economic adjustments, the pan-European STOXX Europe 600 Index shows modest gains, reflecting investor optimism amid global uncertainties. With this backdrop, dividend stocks in Europe present a compelling opportunity for investors seeking stable income streams; these stocks are often characterized by strong fundamentals and consistent payout histories that can provide resilience in fluctuating market conditions.

ABB (SWX:ABBN) has integrated its power systems as SimReady 3D digital assets into NVIDIA's Omniverse DSX Blueprint. The partnership focuses on virtual modeling, validation, and optimization of data center power distribution for AI workloads before facilities are built. The announcement extends ABB's digital twin and AI infrastructure offering for large scale, energy focused data centers. ABB comes into this announcement with the share price at CHF86.1 and very strong recent returns,...

As European markets show cautious optimism amid geopolitical developments and economic adjustments, investors are increasingly focused on identifying growth opportunities with strong fundamentals. In this context, companies with high insider ownership often attract attention as they may indicate a strong alignment of interests between management and shareholders, potentially offering resilience in uncertain market conditions.

Shareholders appeared to be happy with LEM Holding SA's ( VTX:LEHN ) solid earnings report last week. This reaction by...

Novartis (SWX:NOVN) reported long term clinical data for Scemblix showing sustained superior efficacy and a favorable safety profile in chronic myeloid leukemia. The company also released expanded clinical evidence for Pluvicto in prostate cancer, underscoring progress in its radioligand therapy franchise. These data come from pivotal clinical trials and mark important milestones for Novartis in hematology and oncology. For investors tracking large pharma, these updates touch two core...

Landis+Gyr Group (SWX:LAND) is back on investors’ radar after its 2026 Capital Markets Day in New York, where the company outlined new Connected Platforms and Grid Intelligence segments and reaffirmed mid term growth expectations through 2028. See our latest analysis for Landis+Gyr Group. The CHF52.0 share price has seen a 4.31% 1 day share price return around the Capital Markets Day update, while the 1 year total shareholder return of 3.27% contrasts with a decline over the 3 year period of...

Roche Holding (SWX:ROP) is back in focus after a string of late May and early June product updates in obesity treatments and oncology, including fresh U.S. regulatory decisions and new clinical data presentations. See our latest analysis for Roche Holding. Despite the flurry of obesity and oncology updates, momentum in the shares has eased, with the 90 day share price return down 13.68% and the year to date share price return down 4.85%, even as the 1 year total shareholder return stands at...

Recent performance snapshot Idorsia (SWX:IDIA) has attracted fresh attention after a strong rebound over the past year, with the stock up about 166% over that period and showing gains across the past month and past 3 months. For investors tracking shorter time frames, Idorsia shares are up about 6% over the past week and around 19% over the past month, while the past 3 months show a gain of roughly 8%. See our latest analysis for Idorsia. Putting it together, Idorsia’s recent 1-day share...

Dätwyler Holding AG ( VTX:DAE ), is not the largest company out there, but it saw a double-digit share price rise of...

Recent share performance and business profile Compagnie Financière Tradition (SWX:CFT) has drawn investor attention after recent trading, with the stock last closing at CHF 268. The move comes against a mixed pattern of short and longer term returns. Over the past month the share price declined about 9%, and it is down roughly 2% over the past 3 months and 6% year to date. In contrast, the 1 year total return is about 23%, with very large gains over the past 3 and 5 years. The company...

As European markets experience modest gains, with the pan-European STOXX Europe 600 Index advancing slightly and major indices like Germany’s DAX and France’s CAC 40 showing positive movement, investors are keenly observing geopolitical developments that could impact energy markets. In this context, dividend stocks can offer a measure of stability and income potential; they are particularly appealing when market conditions are uncertain or volatile.

Galenica (SWX:GALE) confirmed its 2026 guidance and reiterated expectations for sales growth of 5% to 7% and EBIT growth of 6% to 8%, keeping investor attention on its earnings outlook. See our latest analysis for Galenica. The confirmation of 2026 guidance comes after a period where the share price has lost some momentum. The 90 day share price return is down 12.45% and the year to date share price return is down 15.29%, even as the 5 year total shareholder return of 49.84% points to more...

Nestlé (SWX:NESN) is back in focus after Nestlé Health Science agreed a licensing deal with IdB Holding S.p.A. to develop and commercialize VOWST in Europe, pending approval from the European Medicines Agency. See our latest analysis for Nestlé. The VOWST licensing deal lands at a time when Nestlé’s share price, at CHF79.44, has edged higher year to date, but its 1 year total shareholder return is still down, signalling that longer term momentum has been weak even as recent news shifts...

Recent share performance and basic snapshot Novartis (SWX:NOVN) has seen mixed share performance recently, with the stock down over the past week but higher over the past month, and its total return over the past year above 25%. The company has a market value of about CHF 224.8b, with revenue of $56,578.0m and net income of $13,534.0m from its pharmaceutical operations across cardiovascular, immunology, neuroscience, oncology, and hematology therapies. See our latest analysis for Novartis. At...

UBS Group (SWX:UBSG) is proceeding with significant job cuts as it integrates Credit Suisse into its global operations. The company is restructuring its combined workforce to streamline overlapping functions and adjust its operating model. The Federal Reserve has formally ended enforcement actions against both UBS and Credit Suisse, closing a long running regulatory chapter. These developments arrive as UBS continues its multi year integration process following the Credit Suisse...

As global markets navigate a landscape marked by inflation concerns, geopolitical tensions, and fluctuating consumer sentiment, investors are keenly observing shifts in stock indices. With the Dow Jones Industrial Average reaching an all-time high and small-cap stocks outperforming their larger counterparts, opportunities to identify undervalued stocks have become increasingly appealing. In this environment, a good stock is often characterized by strong fundamentals that may not yet be fully...

Shareholders will be ecstatic, with their stake up 38% over the past week following LEM Holding SA 's ( VTX:LEHN...